Lindagan, Sayba M.

HRN: 07-62-08  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/28/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/28/2025
10/28/2025
IV
350mg
Now
Septicemia Sec To CUTI
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Urinary Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: